AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7034641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceforanide (0.5 g every 12 h)
Number of subjects: 54
Study 7034641 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (1.0 g every 8 h)
Number of subjects: 54
Study 7034641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceforanide
Number of subjects: 54
Study 7034641 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 54
Study 7034641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceforanide and Cefazolin
Number of subjects: 54
Study 29045315 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP supplementation (400 mg)
Number of subjects: 11
Study 29045315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 27696395 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel at a dose of 175 mg/m2 plus nedaplatin at a dose of 80 mg/m2 administered intravenously every 3 weeks
Number of subjects: 27
Study 27696395 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel plus nedaplatin
Number of subjects: 27
Study 26063925 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo analgesia
Number of subjects: 0
Study 26063925 — intervention group
Group type: COMPARATOR
Intervention: Painful electrical stimulation
Number of subjects: 0
Study 25190346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (48 IU)
Number of subjects: 40
Study 25190346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21864416 — intervention group
Group type: EXPERIMENTAL
Intervention: RG-CMH (Chinese medicinal herb complex)
Number of subjects: 58
Study 21864416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 20606545 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at Camp Trillium
Number of subjects: 162
Study 20606545 — intervention group
Group type: COMPARATOR
Intervention: Non-attendance at Camp Trillium
Number of subjects: 162
Study 17645195 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 18
Study 16134110 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction with thin-ideal confederate
Number of subjects: 119
Study 16134110 — intervention group
Group type: COMPARATOR
Intervention: Interaction with average body dimensions confederate
Number of subjects: 119
Study 12387959 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 606
Study 12387959 — intervention group
Group type: COMPARATOR
Intervention: Microemulsified ciclosporin
Number of subjects: 606
Study 9952201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (n = 136)
Number of subjects: 268
Study 9952201 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 132)
Number of subjects: 268
Study 9952201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 268
Study 8534461 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ketorolac IV
Number of subjects: 112
Study 8534461 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ketorolac IM
Number of subjects: 112
Study 8534461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 2725118 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine system (TNS) 10, 20, and 40 mg/24 h
Number of subjects: 0
Study 2725118 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine system (TNS) delivering 14 mg nicotine/24 h
Number of subjects: 0
Study 2725118 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 0
Study 4902196 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-free liver extract (Ripason) administered both orally and intramuscularly
Number of subjects: 20
Study 4902196 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 31068405 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV text message
Number of subjects: 17
Study 31068405 — intervention group
Group type: COMPARATOR
Intervention: Control text message
Number of subjects: 17
Study 28184153 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD)
Number of subjects: 328
Study 28184153 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 328
Study 28184153 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignancy
Number of subjects: 328
Study 28184153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia
Number of subjects: 328
Study 28184153 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF), chronic kidney disease (CKD), and visual impairment
Number of subjects: 328
Study 28184153 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension, chronic kidney disease (CKD), and malignancy
Number of subjects: 328
Study 26520572 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC plus food assistance
Number of subjects: 788
Study 26520572 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC plus cash transfer
Number of subjects: 788
Study 26520572 — intervention group
Group type: COMPARATOR
Intervention: NAC only
Number of subjects: 788
Study 24937390 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-modality therapy (DMT) - cryotherapy and 15% methyl salicylate phonophoresis
Number of subjects: 60
Study 24937390 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoresis (PHONO) - 15% methyl salicylate phonophoresis
Number of subjects: 60
Study 24937390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (CRYO) - cryotherapy and 'sham' phonophoresis
Number of subjects: 60
Study 24937390 — intervention group
Group type: COMPARATOR
Intervention: All groups (DMT, PHONO, CRYO)
Number of subjects: 60
Study 24937390 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-modality therapy (DMT)
Number of subjects: 60
Study 21689019 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol by pressurized metered-dose inhaler (pMDI) 12 μg b.i.d.
Number of subjects: 48
Study 21689019 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol by dry powder inhaler (DPI) 12 μg b.i.d.
Number of subjects: 48
Study 21689019 — intervention group
Group type: COMPARATOR
Intervention: Formoterol by pMDI or DPI
Number of subjects: 48
Study 21689019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 18687132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antioxidant supplements (selenium 270 microg, zinc 30 mg, vitamin C 1.1 g, and vitamin B1 100 mg) for 5 days with a double-loading dose on days 1 and 2
Number of subjects: 200
Study 18687132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antioxidant supplements
Number of subjects: 200
Study 18687132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 22238967 — intervention group
Group type: EXPERIMENTAL
Intervention: Annuloplasty of the mitral valve fibrous ring with a synthetic band
Number of subjects: 0
Study 22238967 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15938902 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented posterior fusion (Group A)
Number of subjects: 45
Study 15938902 — intervention group
Group type: COMPARATOR
Intervention: Instrumented circumferential lumbar fusion (Group B)
Number of subjects: 45
Study 12631424 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan orally
Number of subjects: 29
Study 12631424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9850897 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 drops of lidocaine 4% before surgery
Number of subjects: 20
Study 9850897 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 drops of lidocaine 4% before surgery
Number of subjects: 20
Study 9850897 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 drops of lidocaine 4% plus intracameral injection of 0.1 mL lidocaine 1%
Number of subjects: 20
Study 7913157 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 1240
Study 7913157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1240
Study 2531908 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvalent melanoma cell vaccine alone
Number of subjects: 0
Study 2531908 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvalent melanoma cell vaccine with low-dose cyclophosphamide
Number of subjects: 0
Study 2531908 — intervention group
Group type: EXPERIMENTAL
Intervention: Other immunomodulators (alone or in combination with lower doses of cyclophosphamide)
Number of subjects: 0
Study 11711455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention trials on treatment of acute myocardial infarction
Number of subjects: 31
Study 11711455 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise verbal information about the study
Number of subjects: 31
Study 11711455 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician decision-making in case of patient incapacity
Number of subjects: 31
Study 31386987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), 12 sessions
Number of subjects: 65
Study 31386987 — intervention group
Group type: COMPARATOR
Intervention: Waiting period (control group)
Number of subjects: 65
Study 31386987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 65
Study 29438425 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate cauterization
Number of subjects: 207
Study 29438425 — intervention group
Group type: COMPARATOR
Intervention: Topical steroid ointment
Number of subjects: 207
Study 27328792 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-CT
Number of subjects: 397
Study 27328792 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional imaging)
Number of subjects: 397
Study 24320943 — intervention group
Group type: EXPERIMENTAL
Intervention: High independence centrality
Number of subjects: 173
Study 24320943 — intervention group
Group type: EXPERIMENTAL
Intervention: Low independence centrality
Number of subjects: 173
Study 24320943 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased disability
Number of subjects: 173
Study 24320943 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher independence centrality at baseline
Number of subjects: 173
Study 22298017 — intervention group
Group type: EXPERIMENTAL
Intervention: combined intervention
Number of subjects: 3490
Study 22298017 — intervention group
Group type: COMPARATOR
Intervention: parent intervention
Number of subjects: 3490
Study 22298017 — intervention group
Group type: COMPARATOR
Intervention: student intervention
Number of subjects: 3490
Study 22298017 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 3490
Study 20150825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and pemetrexed (CP)
Number of subjects: 126
Study 20150825 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and gemcitabine (CG)
Number of subjects: 126
Study 17390924 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative education and patient education pamphlet, standard nursing care plan and nursing care protocol applied in the postoperative period for Group 2 subjects
Number of subjects: 32
Study 17390924 — intervention group
Group type: COMPARATOR
Intervention: Nursing care needs assessment through interviews and observations in Group 1
Number of subjects: 32
Study 15204669 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine with buprenorphine
Number of subjects: 164
Study 15204669 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine with methadone
Number of subjects: 164
Study 15204669 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 164
Study 15204669 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 164
Study 15204669 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 164
Study 15204669 — intervention group
Group type: COMPARATOR
Intervention: Placebo desipramine
Number of subjects: 164
Study 15204669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-free urines
Number of subjects: 164
Study 11782569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride, 20 mg b.i.d., during 4 weeks
Number of subjects: 30
Study 11782569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10095800 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin daily for 6 weeks, followed by 80 mg atorvastatin for another 6 weeks
Number of subjects: 41
Study 10095800 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 41
Study 10095800 — intervention group
Group type: COMPARATOR
Intervention: 40 mg simvastatin alone
Number of subjects: 41
Study 10095800 — intervention group
Group type: COMPARATOR
Intervention: 40 mg simvastatin with 8-12 g colestyramin
Number of subjects: 41
Study 10095800 — intervention group
Group type: COMPARATOR
Intervention: 40 mg simvastatin with 1800 mg nicotinic acid
Number of subjects: 41
Study 8074019 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 2.5 mg
Number of subjects: 117
Study 8074019 — intervention group
Group type: COMPARATOR
Intervention: Captopril 6.25 mg
Number of subjects: 117
Study 2590602 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% bromocriptine eye drops
Number of subjects: 9
Study 2590602 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% timolol eye drops
Number of subjects: 9
Study 2590602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 4548791 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative programme
Number of subjects: 0
Study 4548791 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29500292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous elamipretide (0.25 mg/kg/h)
Number of subjects: 36
Study 29500292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29500292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous elamipretide (highest dose)
Number of subjects: 36
Study 28774642 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma‐Lyte 148 (PL‐148)
Number of subjects: 954
Study 28774642 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 954
Study 25551405 — intervention group
Group type: EXPERIMENTAL
Intervention: ST + a‐tDCS
Number of subjects: 24
Study 25551405 — intervention group
Group type: COMPARATOR
Intervention: ST + sham
Number of subjects: 24
Study 25551405 — intervention group
Group type: COMPARATOR
Intervention: a‐tDCS
Number of subjects: 24
Study 24617231 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture and manual manipulation (group A)
Number of subjects: 160
Study 24617231 — intervention group
Group type: COMPARATOR
Intervention: Simple manual manipulation (group B)
Number of subjects: 160
Study 21676990 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 10 weeks
Number of subjects: 80
Study 21676990 — intervention group
Group type: COMPARATOR
Intervention: Clinical monitoring (no new treatment)
Number of subjects: 80
Study 21676990 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 80
Study 17579653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecoimmunonutrition (EIN) group supplied by Lactobacillus plantarum enteral feeding (n=36)
Number of subjects: 76
Study 17579653 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (PN) group (n=38)
Number of subjects: 76
Study 17065036 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma volume expansion (n = 18)
Number of subjects: 74
Study 17065036 — intervention group
Group type: EXPERIMENTAL
Intervention: No plasma volume expansion (n = 19)
Number of subjects: 74
Study 17065036 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnancy controls (n = 29)
Number of subjects: 74
Study 17065036 — intervention group
Group type: COMPARATOR
Intervention: Late-onset preeclampsia controls (n = 8)
Number of subjects: 74
Study 12824815 — intervention group
Group type: EXPERIMENTAL
Intervention: 21‐mg nicotine patch
Number of subjects: 115
Study 12824815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 10873077 — intervention group
Group type: EXPERIMENTAL
Intervention: i.p. recombinant IFN-gamma (rIFN-gamma), 200 microg/m2 on days 1, 3, 5, 8, 10, and 12 and i.p. recombinant interleukin 2 (rIL-2), 6.0 x 10(5) IU/m2 (group A) on days 9, 10, and 11
Number of subjects: 22
Study 10873077 — intervention group
Group type: EXPERIMENTAL
Intervention: i.p. recombinant IFN-gamma (rIFN-gamma) and rIL-2 plus TILs
Number of subjects: 22
Study 10873077 — intervention group
Group type: EXPERIMENTAL
Intervention: i.p. recombinant IFN-gamma (rIFN-gamma) and rIL-2
Number of subjects: 22
Study 10873077 — intervention group
Group type: EXPERIMENTAL
Intervention: i.p. recombinant IFN-gamma (rIFN-gamma) plus rIL-2
Number of subjects: 22
Study 10873077 — intervention group
Group type: EXPERIMENTAL
Intervention: i.p. recombinant IFN-gamma (rIFN-gamma) and higher rIL-2 dosing (group A)
Number of subjects: 22
Study 10873077 — intervention group
Group type: EXPERIMENTAL
Intervention: i.p. recombinant IFN-gamma (rIFN-gamma) and lower rIL-2 dosing (group B)
Number of subjects: 22
Study 8879704 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium clodronate, total daily dose of 1600‐3200 mg
Number of subjects: 0
Study 2000517 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine
Number of subjects: 50
Study 2000517 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 50
Study 2000517 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 6229564 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (300 mg mean maintenance dosage, range 200-350 mg)
Number of subjects: 26
Study 6229564 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (160 mg mean maintenance dosage, range 150-175 mg)
Number of subjects: 26
Study 6229564 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 26
Study 6229564 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 26
Study 31107560 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of lidocaine‐and‐prilocaine (LP) cream for 120 minutes
Number of subjects: 0
Study 30061318 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 90
Study 30061318 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 90
Study 26848561 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg twice daily added to subcutaneous interferon β‐1a therapy
Number of subjects: 304
Study 26848561 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to subcutaneous interferon β‐1a therapy
Number of subjects: 304
Study 24247661 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics in cow's milk from birth to 6 months
Number of subjects: 253
Study 24247661 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk without probiotics
Number of subjects: 253
Study 22100490 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal radiofrequency hyperthermia (TRFH)
Number of subjects: 159
Study 22100490 — intervention group
Group type: EXPERIMENTAL
Intervention: TRFH with tamsulosin plus clarithromycin
Number of subjects: 159
Study 22100490 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin plus clarithromycin
Number of subjects: 159
Study 22100490 — intervention group
Group type: EXPERIMENTAL
Intervention: TRFH
Number of subjects: 159
Study 18974025 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg b.d. and amoxicillin 1g b.d. plus levofloxacin 500 mg o.d. for 7 days (Group A)
Number of subjects: 160
Study 18974025 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg b.d. and amoxicillin 1g b.d. plus levofloxacin 500 mg o.d. for 10 days (Group B)
Number of subjects: 160
Study 18974025 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg b.d. for 7 days (Group C)
Number of subjects: 160
Study 18974025 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg b.d. for 10 days (Group D)
Number of subjects: 160
Study 18974025 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days treatment (Groups A and C)
Number of subjects: 160
Study 18974025 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 days treatment (Groups B and D)
Number of subjects: 160
Study 18974025 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily levofloxacin (Group B)
Number of subjects: 160
Study 18974025 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily levofloxacin (Groups C and D)
Number of subjects: 160
Study 18974025 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 160
Study 17141851 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 16
Study 17141851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15854188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg as needed
Number of subjects: 140
Study 15854188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 11980623 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 g testosterone gel daily for 10 days
Number of subjects: 26
Study 11980623 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g testosterone gel daily for 10 days
Number of subjects: 26
Study 11980623 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 g testosterone gel with washing off after 10 min
Number of subjects: 26
Study 10635200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic abutments
Number of subjects: 32
Study 10635200 — intervention group
Group type: COMPARATOR
Intervention: Titanium abutments
Number of subjects: 32
Study 10635200 — intervention group
Group type: EXPERIMENTAL
Intervention: Both abutments
Number of subjects: 32
Study 7871179 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0
Study 7871179 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 7871179 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 7871179 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 0
Study 7871179 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0